美股異動 | 維羅納製藥盤前漲超 80% Ensifentrine 成功達到試驗主要和次要終點

第一財經
2022.12.20 09:09
格隆匯 12 月 20 日 | 維羅納製藥 (VRNA.US) 盤前漲超 80%，報 24.74 美元。該公司今天宣佈 ENHANCE-1 3 期試驗的積極結果，該試驗評估了霧化 Ensifentrine 對慢性阻塞性肺疾病的維持治療。Ensifentrine 成功地達到了其主要和次要終點，顯示出肺功能、症狀和生活質量方面的明顯改善。此外，Ensifentrine 大大降低了慢性阻塞性肺疾病惡化的速度和風險。Ensifen
Source: 第一財經 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.